Trial · NCT03088293
Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)
NCT03088293, Phase 3, Withdrawn, Hospices Civils de Lyon
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS). Trials, record NCT03088293. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03088293
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)
- NCT number
- NCT03088293
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Hospices Civils de Lyon
- Conditions
- Idiopathic Refractory Scleritis
- Interventions
- Infliximab, Cyclophosphamide
- First posted
- 2017-03-23
- Last updated
- 2022-07-20
- Other registries' IDs
- eudract:2017-004969-27
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | percentage of patients with resolution (score=0) of the scleral inflammation and with a prednisone dose lower than 0.1 mg/kg/day | Week 20 | Scleritis will be graded and scored according to the grading system defined by Sen for sclera inflammation (gradings from 0 to 4): these findings will be documented by drawings, photography or both for central review. |
| Secondary | percentage of patients with a decrease of at least 2 in sclera inflammation with a prednisone dose lower or equal to 0.1 mg/kg/day. | Week 20 | according to Sen and al gradation at week 20 and with a prednisone dose lower or equal to 0.1 mg/kg/day. |
| Secondary | Mean change in sclera inflammation from baseline to Week 20. | Week 20 | from baseline to Week 20 (according to Sen and al gradation) |
| Secondary | Time to response onset (total resolution in sclera inflammation). | Week 26 | |
| Secondary | Mean change in Best corrected visual acuity | Week 20 | from baseline to week 20 (ETDRS letter score) |
| Secondary | percentage of patients meeting targets: ≤ 0.1 mg/day prednisone | Week 20 | |
| Secondary | mean change dose of corticosteroid | Week 26 | * mean dose at week 20, * cumulative dose. |
| Secondary | Mean dose of corticosteroid | Week 20 | |
| Secondary | Cumulative dose of corticosteroid | Week 26 | |
| Secondary | Frequency to relapse of scleritis | Week 26 | Relapse will be diagnosed when inflammation will restart within 6 months of tapering or discontinuation of medication.Early relapse will be distinguished to later relapse. Early relapse corresponds to any scleritis relapse within the 3 months after discontinuation of medication and later relapse corresponds to any scleritis relapse after 3 months after discontinuation of medication. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03088293
GET https://conductscience.org/api/trials/v1/NCT03088293/registered